The finding that EGFR mutations in primary lung cancer are associated with sensitivity to EGFR inhibitors gefitinib and erlotinib [44, 60, 61] contributed greatly to the final approval of these therapeutics for the treatment of lung cancer. This evidence concerns the gene EGFR and lung cancer.